Faculty Opinions recommendation of Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebo-controlled trial.

Authors:

Abstract
This double-blind randomized, placebo-controlled trial found no beneficial effect of treating tuberculosis (TB) patients with vitamin D. The study is useful because controlled trials of the usefulness of vitamin D in reducing TB clinical severity and mortality have not been performed using large numbers of patients; there have been lots of uncontrolled studies and here-say evidence suggesting that vitamin D administration to TB patients would be a useful addition to their therapy. Vitamin D is a cheap and easily administered therapy. It was used in the pre-antibiotic era to aid recovery of TB sufferers, although there was no properly controlled scientific evidence to show that it improved the outcome. Large-scale controlled trials of the efficacy of vitamin D in improving response to treatment of individuals who have contracted TB have not been performed. If the therapy could be shown to be beneficial, it would be an extremely attractive option to include as part of the treatment of patients who present with the disease. This is especially since it is cheap and easy to administer, which is important because the majority of TB sufferers are located in resource-constrained settings. A talk that I attended recently presented data suggesting that many people in the general population are vitamin D deficient. Therefore, it might be expected that deficiency could well be high in many TB patients too. In this study, 365 adults were included, of which 281 completed the 12-month follow-up (187 of these received vitamin D therapy and 178 received placebo). No overall benefit was found with the administration of vitamin D in reducing clinical severity or 12-month mortality compared to administration of a placebo. It should be noted that the dose used here was 100,000 IU whereas previous studies (although not properly controlled) suggesting a benefit to the vitamin D therapy used much higher doses -- 600,000 IU. Therefore, it may be worth repeating the study with a higher dose. I would note that vitamin D is produced in the skin when 7-dehydrocholesterol reacts with UV light. Therefore, it might be expected that in the summer in temperate regions and in some places year-round that vitamin D deficiency may be less prevalent. This study was done in Guinea-Bissau where the temperature averages 26 degrees year-round. This, therefore, supports that large numbers of the participants enrolled had a normal vitamin D level before the intervention. It may be worth repeating the study in a country where vitamin D deficiency is more prevalent. This study is strong in that it is the first proper controlled trial looking at this treatment compared to placebo in several hundred patients. It would be useful to use this study as a platform to repeat in a different population where vitamin D deficiency is higher and perhaps prescribe a higher intervention dose. Alternatively, it would be more revealing if there were several arms in the study with several different doses to reveal whether the amount administered is critical in the outcome.